Clinical trial

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-03-01

PhasePHASE3

Study timeline

Study start (unknown)2007-03-01Date precision: month

Registry last updated2014-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

RISPERDAL CONSTADRUG

Paliperidone palmitateDRUG · verified · RxNorm: paliperidone palmitate

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Mapped research locations

HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 AtlantaGeorgia, United States1 MadridSpain1 BarcelonaSpain1 BirminghamAlabama, United States1 BerlinGermany1 Washington D.C.District of Columbia, United States1 Oklahoma CityOklahoma, United States1 MoscowRussia1 BudapestHungary1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00589914 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.